GSE151412 In vivo screen identifies LXR agonism potentiates sorafenib killing of hepatocellular carcinoma

Conclusions: We have completed a novel drug resistance screen in vivo, and identified that LXR agonism potentiates the efficacy of sorafenib in treating HCC.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Related Links:

Publication date: Available online 13 July 2020Source: Journal of Advanced ResearchAuthor(s): Jong Hyun Lee, Chakrabhavi Dhananjaya Mohan, Amudha Deivasigamani, Young Yun Jung, Shobith Rangappa, Salundi Basappa, Arunachalam Chinnathambi, Tahani Awad Alahmadi, Sulaiman Ali Alharbi, Manoj Garg, Zhi-Xiu Lin, Kanchugarakoppal S. Rangappa, Gautam Sethi, Kam Man Hui, Kwang Seok Ahn
Source: Journal of Advanced Research - Category: Research Source Type: research
Authors: Zheng YJ, Li DL, Luo, Chen XP, Zhang B, Fang C, Gan Y, Li B, Su S Abstract OBJECTIVE: Here, we aimed to compare early hepatectomy (EH) with delayed hepatectomy (DH) as a treatment for spontaneously ruptured hepatocellular carcinoma (HCC). METHODS: Several databases were systematically searched for eligible studies that compared DH with EH for spontaneously ruptured HCC treatment. Studies that met the inclusion criteria were reviewed systematically, and the reported data were aggregated statistically, using the RevMan v5.3 software. RESULTS: Seven studies were included, with a total of 385 patients,...
Source: Journal of Investigative Surgery - Category: Surgery Tags: J Invest Surg Source Type: research
The objective response rates (ORRs) were 61.8% in first-line, 33.3% in second-line, and 20.0% in third-line groups. The overall survival (OS) in the first-line was significantly longer than that in the third-line group (p
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conclusions: Future studies are awaited to define best candidates for novel agents approved in the second line of treatment for HCC. PMID: 32655640 [PubMed]
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Nonalcoholic fatty liver disease (NAFLD) is becoming a major health issue as obesity increases around the world. We studied the effect of a circadian locomotor output cycles kaput (CLOCK) mutant (ClkΔ19/Δ19) protein on hepatic lipid metabolism in C57BL/6 Clkwt/wt and apolipoprotein E–deficient (Apoe−/−) mice. Both ClkΔ19/Δ19 and ClkΔ19/Δ19 Apoe−/− mice developed a full spectrum of liver diseases (steatosis, steatohepatitis, cirrhosis, and hepatocellular carcinoma) recognized in human NAFLD when challenged with a Western diet, lipopolysaccharide, or CoCl2. We...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
ConclusionsThe CUAs for CHC were found to apply to various HSUVs from different utility elicitation studies in the same health state. This variability in HSUVs has the potential to significantly affect ICER and ICER-based reimbursement decisions. A rigorous selection of HSUVs in CUAs to inform healthcare resource allocation is suggested for future studies of CUAs and for guideline development.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
In conclusion, combination of sorafenib + pravastatin was safe and well-tolerated, prolonging the TTP of patients with aHCC but not improving the OS compared to sorafenib + placebo. The absence of PVT and VI and the development of DE are positive prognostic factors of sorafenib response.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Cancer & Oncology | Carcinoma | Databases & Libraries | Genetics | Hepatocellular Carcinoma | Liver | Liver Cancer | Urology & Nephrology